Stock listing

NASDAQ:BIVI BioVie Inc. Stock

Home listing (NASDAQ) of BioVie Inc.

Follow BioVie Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BIVI

$0.80 USD -0.14 (-15.1%)

Close on Nov 20, 2026

Past year -37.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.752 – $0.91 USDNov 20, 2026
Volume
399,581 sharesNov 20, 2026
Market cap
$8.58M USDAt the close on Nov 20, 2026 · price × 10.72M shares outstanding
52-week range
$0.752 – $3.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.96M USDMedian day 250,794 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
BioVie Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BIVI · Home$0.80 USD-0.143 (-15.1%)399,581$0.897$0.91$0.752$0.943Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BIVI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.80-0.143-15.1%$0.897$0.91$0.752399,581
$0.943-0.052-5.3%$1.04$1.046$0.93183,511
$0.995-0.085-7.8%$1.08$1.08$0.94439,854
$1.08-0.05-4.4%$1.15$1.165$1.06158,729
$1.13-0.06-5.0%$1.19$1.23$1.13214,938
$1.19-0.07-5.6%$1.23$1.24$1.16163,103
$1.26-0.01-0.8%$1.28$1.32$1.24137,606
$1.27-0.03-2.3%$1.29$1.35$1.25295,658
$1.30-0.03-2.3%$1.40$1.40$1.28164,364
$1.33+0.12+9.9%$1.25$1.38$1.23184,386
$1.21-0.13-9.7%$1.29$1.31$1.105488,213
$1.34-0.39-22.5%$1.64$1.65$1.231,108,131
$1.73+0.36+26.3%$1.45$2.66$1.4013,523,350
$1.37-0.06-4.2%$1.41$1.43$1.31120,889
$1.43+0.05+3.6%$1.39$1.49$1.38105,100
$1.38-0.08-5.5%$1.43$1.46$1.3741,900
$1.46+0.02+1.4%$1.49$1.49$1.412106,700
$1.44+0.11+8.3%$1.37$1.45$1.34195,900
$1.33+0.09+7.3%$1.25$1.36$1.25139,000
$1.24-0.04-3.1%$1.28$1.30$1.23141,650
$1.28+0.02+1.6%$1.24$1.29$1.215101,048
$1.26+0.02+1.6%$1.21$1.277$1.15195,074
$1.24-0.13-9.5%$1.40$1.45$1.24279,510
$1.37+0.17+14.2%$1.29$1.39$1.204182,520
$1.20+0.07+6.2%$1.13$1.22$1.12275,926
$1.13-0.03-2.6%$1.18$1.19$1.13166,880
$1.16-0.04-3.3%$1.20$1.25$1.15342,644
$1.20-0.12-9.1%$1.30$1.331$1.20171,968
$1.32-0.07-5.0%$1.41$1.441$1.3167,349
$1.39+0.11+8.6%$1.30$1.40$1.275204,863
$1.28-0.12-8.6%$1.37$1.39$1.25362,156
$1.40-0.04-2.8%$1.46$1.47$1.40134,616
$1.440.000.0%$1.44$1.50$1.44132,707
$1.44-0.02-1.4%$1.43$1.48$1.42135,119
$1.46-0.01-0.7%$1.47$1.52$1.46189,852
$1.47-0.05-3.3%$1.53$1.535$1.46266,171
$1.52-0.02-1.3%$1.57$1.58$1.50201,338
$1.540.000.0%$1.55$1.61$1.52146,520
$1.54-0.065-4.0%$1.57$1.60$1.53182,616
$1.605-0.005-0.3%$1.66$1.75$1.58458,952
$1.61-0.02-1.2%$1.60$1.645$1.595235,841
$1.630.000.0%$1.63$1.66$1.59216,462
$1.630.000.0%$1.65$1.71$1.61201,659
$1.63+0.02+1.2%$1.64$1.76$1.62411,521
$1.61-0.17-9.6%$1.78$1.84$1.61406,800
$1.78+0.06+3.5%$1.82$1.841$1.75478,847
$1.72-0.03-1.7%$1.76$1.825$1.685439,983
$1.75-0.30-14.6%$1.90$1.908$1.5651,154,667
$2.05+0.12+6.2%$1.90$2.12$1.88630,141
$1.93+0.02+1.0%$1.92$2.02$1.91170,760
$1.91-0.06-3.0%$1.95$1.99$1.89261,851
$1.97-0.10-4.8%$2.04$2.12$1.90351,367
$2.07+0.07+3.5%$2.055$2.20$2.00320,028
$2.00-0.03-1.5%$2.04$2.08$1.96296,762
$2.030.000.0%$2.02$2.12$2.005250,794
$2.03-0.21-9.4%$2.25$2.27$2.00519,399
$2.24-0.04-1.8%$2.30$2.45$2.18486,559
$2.28+0.12+5.6%$2.374$2.49$2.281,551,930
$2.16-0.03-1.4%$2.20$2.25$2.106485,693
$2.19+0.08+3.8%$2.09$2.22$2.00763,384
$2.11+0.02+1.0%$2.005$2.25$1.967922,448
$2.09-0.05-2.3%$2.00$2.11$1.931,029,902
$2.14+0.19+9.7%$1.812$2.145$1.762,173,771
$1.95+0.09+4.8%$2.155$2.48$1.8019,763,840
$1.86+0.52+38.8%$1.545$2.39$1.4949,110,641

Splits

2 splits since 2024 · NASDAQ:BIVI · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-10Consolidation
Ticker
NASDAQ:BIVI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All BioVie Inc. news

BioVie Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 120 in all · newest Nov 16, 2026 · oldest 2019
Decks
25 decks · latest Oct 23, 2025

Where BioVie Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BIVI · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BIVIBOATSUnited StatesUSD

Valuation

Price/book 1.3× against a median of 1.0×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.10M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.84

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BioVie Inc. · NASDAQ:BIVIUS$8.58MUS$1.10Mn/an/an/a1.3×n/a0.0×1.84
PreveCeutical Medical Inc · CSE:PREVUS$8.97MUS$8.95Mn/an/an/an/an/an/a0.73
BioLineRX Ltd. · TASE:BLRXUS$8.90MUS$10.13Mn/a8.6×n/a0.5×−171.7%0.3×n/a
CalciMedica, Inc. · NASDAQ:CALCUS$8.69MUS$1.82Mn/an/an/a2.1×n/a1.6×0.54
Active Biotech AB · OMXSTO:ACTIUS$8.66MUS$4.38Mn/an/an/a2.4×n/a0.0×n/a
Vyome Holdings, Inc. · NASDAQ:HINDUS$8.42MUS$1.82Mn/a11.9×n/a1.3×n/a0.1×1.34
CRISM Therapeutics Corporation · LSE:CRTXUS$8.34MUS$5.37Mn/a17.8×n/a2.5×−823.8%0.0×n/a
Brainstorm Cell Therapeutics Inc. · OTC:BCLIUS$8.31MUS$10.08Mn/an/an/an/an/an/a0.40
Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTMUS$8.29M−US$3.20Mn/an/an/a0.7×n/a0.1×1.05
Moleculin Biotech, Inc. · NASDAQ:MBRXUS$8.22MUS$1.04Mn/an/an/a0.6×n/a0.0×0.42
IN8bio, Inc. · NASDAQ:INABUS$8.19M−US$3.03Mn/an/an/a0.6×n/a0.2×1.25
Median of the othersUS$8.38MUS$3.10M11.9×1.0×−497.8%0.1×0.73

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
5.25 USD · Analysts' mean
EPS, year to Jun 2027
-0.63 · 1 analyst

Team and board

Officers

OfficerRole
Cuong DoPresident & Chief Executive Officer
Wendy KimChief Financial Officer
Chris ReadingSenior Vice President Alzheimer's Disease Program
Clarence AhlemSenior Vice President Operations
David MorseChief Regulatory Officer and Senior Vice President
Joseph M. PalumboExecutive Vice President, Research & Development and Chief Medical Officer
Penelope MarkhamSenior Vice President Liver Disease and Long COVID Programs

Board

DirectorRole
Amy ChappellIndependent Director
Cuong DoPresident & Chief Executive Officer
Jim LangIndependent Director
Kameel FaragIndependent Director
Michael ShermanIndependent Director
Sig RogichIndependent Director

Events

QuarterResultsShare move
Q1 2027Nov 6, 2026 · After close−2.3%
Q4 2026Aug 12, 2026+22.8%
Q3 2026Jun 3, 2026+1.2%
Q2 2026Feb 25, 2026+1.6%
Q1 2026Nov 10, 2025 · After close−3.2%
Q4 2025Aug 15, 2025 · After close+6.1%
Q3 2025May 12, 2025 · After close−7.0%
Q2 2025Feb 11, 2025 · After close−3.9%
Q1 2025Nov 6, 2024 · After close+10.0%
Q4 2024Sep 30, 2024 · After close−4.2%
All 20 quarters
QuarterResultsShare move
Q3 2024May 14, 2024 · After close−0.8%
Q2 2024Feb 13, 2024 · Before open−3.5%
Q1 2024Nov 8, 2023 · After close−29.3%
Q4 2023Aug 16, 2023 · After close−5.6%
Q3 2023May 12, 2023 · After close+0.9%
Q2 2023Feb 10, 2023 · After close+2.6%
Q1 2023Nov 4, 2022 · After close+0.2%
Q4 2022Sep 27, 2022 · After close+8.5%
Q3 2022May 11, 2022 · After close−0.8%
Q2 2022Feb 8, 2022 · Before open+2.2%

Open Events

Decks

DeckKindSlidesDate
Longevity Biotech, Boston, MA (October 2025)Conference22 slidesOct 23, 2025
Investor Presentation (April 2025)Investor deck44 slidesApril 2025
2024 World Congress on Parkinson's Disease and Related DisordersConference13 slidesMay 2024
12th Annual Alzheimer's and Parkinson's Drug Development Summit 2024Conference27 slidesApril 2024
Investor Presentation (March 2024)Investor deck34 slidesMar 6, 2024
2024 International Conference on Alzheimer's and Parkinson's Diseases and Related NeurologConference14 slidesMarch 2024
ARDD Copenhagen 2024Conference22 slides2024
RedChip Group Investor Webinar December 2023Conference12 slidesDec 7, 2023
Technical Presentation (November 2023)Technical13 slidesNov 29, 2023
Corporate Update (November 2023)Corporate update13 slidesNov 29, 2023
All 25 decks
DeckKindSlidesDate
CTAD conference call 2023Conference9 slidesNov 1, 2023
2023 Clinical Trials on Alzheimer's Disease (CTAD) ConferenceConference15 slidesOct 24, 2023
Investor Presentation (September 2023)Investor deck60 slidesSep 11, 2023
Technical Presentation (August 2023)Technical8 slidesAug 27, 2023
Technical Presentation (June 2023)Technical9 slidesJun 23, 2023
2023 Society of Biological Psychiatry Annual MeetingConference23 slidesApr 27, 2023
Investor Day (March 2023)Investor day79 slidesMar 23, 2023
Investor Presentation (December 2022)Investor deck47 slidesDec 7, 2022
2022 Clinical Trials on Alzheimer's Disease (CTAD) ConferenceConference16 slidesDec 2, 2022
Corporate Update (September 2022)Corporate update65 slidesSep 7, 2022
Investor Presentation (June 2022)Investor deck33 slidesJun 29, 2022
Investor Day (May 2021)Investor day67 slidesMay 17, 2021
Investor Presentation (May 2021)Investor deck52 slidesMay 17, 2021
B. Riley Neuroscience Conference 2021Conference19 slidesApr 29, 2021
Corporate Update (April 2021)Corporate update22 slidesApr 27, 2021

Open Decks

Financings

RaiseDate
Registered direct offering of shares of common stock and concurrent private placement common warrants
Announced: about US$4.74M · US$1.6 a share · ½ warrant at US$1.7 for 66 months · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Use of proceeds: Working capital and general corporate purposes
Nov 4, 2026
Public offering of units (one share of common stock and one warrant) or pre-funded units
Closed: US$12M raised · US$2 a unit · 1 warrant at US$2.5 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Working capital and general corporate purposes
Aug 11, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue0000000000
Cost of revenue229.4K229.4K266.8K237.4K229.4K229.4K229.4K229.4K229.4K
Gross profit-229.4K-229.4K-266.8K-237.4K-229.4K-229.0K-229.0K-229.0K-229.0K
Research and development14.0M9.27M23.1M33.3M17.3M2.54M1.15M1.01M370.9K466.4K
Selling, general and administrative8.51M8.57M8.85M11.6M9.77M4.64M1.31M1.26M1.77M69.1K
Operating income-22.7M-18.1M-32.2M-45.1M-27.3M-138.1M-2.69M-2.50M-2.37M-1.55M
Depreciation and amortization178.3K229.4K229.4K229.4K229.4K229.4K229.4K229.4K229.4K229.4K
EBITDA-22.5M-17.8M-32.0M-44.9M-27.0M-137.8M-2.46M-2.27M-2.14M-1.32M
Interest expense17.9K332.7K2.89M4.30M2.16M559.5K4.77M27341.0K222.9K
Income before tax-22.1M-17.5M-32.1M-50.3M-26.1M-130.2M-16.7M-2.44M-2.41M-1.33M
Income tax-229.4K4.30M-3.29M559.5K4.77M-51.4K-1-223.0K
Net income-22.1M-17.5M-32.1M-50.3M-26.1M-130.2M-16.7M-2.44M-2.43M-1.33M
Earnings per share, basic-3.05-12.12-73.05-15.47-1.06-14.82-6.85-0.98-0.03-0.01
Earnings per share, diluted-3.05-12.12-73.05-15.47-1.06-14.82-6.85-0.98-0.03-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents8.98M17.5M23.8M19.5M18.6M4.51M37.2K339.9K45.8K5.14K
Short-term investments014.5M0000
Receivables2.15M2.10M
Inventory000
Current assets13.6M20.7M24.0M34.0M18.8M4.61M413.0K674.1K45.8K5.14K
Property, plant and equipment80.8K118.3K000
Goodwill345.7K345.7K345.7K345.7K345.7K345.7K345.7K345.7K345.7K345.7K
Total assets14.3M21.6M25.2M35.1M20.1M6.05M2.08M2.57M2.18M2.36M
Accounts payable3.70M2.20M3.59M3.48M2.44M996.4K1.26M443.5K884.2K471.0K
Current liabilities3.80M2.27M9.35M14.5M4.17M996.4K23.5M443.5K1.24M631.0K
Long-term debt5.23M12.1M62.5K0825.9K575.9K
Total debt275.4B349.9K6.11M14.4M12.3M62.5K825.9K35.0K
Total liabilities3.98M2.55M9.70M19.8M16.4M996.4K23.6M443.5K2.06M1.21M
Shareholders' equity10.3M19.0M15.5M15.3M3.67M5.05M-21.5M2.13M111.2K1.16M
Shares outstanding7.54M1.91M619.0K3.64M25.0M22.3M5.20M4.06M98.5M91.9M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-19.0M-19.0M-27.9M-40.3M-19.0M-10.5M-1.63M-2.50M-621.3K-623.6K
Capital spending0-5-400-30000
Free cash flow-19.0B-19.0M-27.9M-40.3M-19.0M-10.5M-1.63M-2.50M-621.3K-623.6K
Cash from investing14.5M-14.3M-14.3M-14.3M-14.3M000
Cash from financing10.5M12.7M17.8M55.4M33.1M14.9M1.33M2.80M662.0K505.0K
Dividends paid-369.5B-886.4K-53.6M-17.1M-48.7K00
Share buybacks18.5M-1.10M00
Change in cash-8.57M-6.30M4.38M819.2K14.1M4.47M-302.7K294.1K40.7K-118.6K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
DNov 18, 2026Other filingsSEC
S-8 · Registration statement for employee plansNov 18, 2026Offer documentSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
8-K · Current reportNov 10, 2026Meeting outcomeSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
8-K · Current reportNov 6, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
424B5 · ProspectusNov 4, 2026Offer documentSEC
424B5 · ProspectusNov 4, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
424B5 · ProspectusNov 4, 2026Offer documentSEC
DEF 14A · Proxy statementSep 28, 2026Meeting noticeSEC
8-K · Current reportSep 11, 2026Material contractSEC
424B5 · ProspectusSep 11, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeSep 3, 2026Big-stake noticeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 19, 2026Big-stake noticeSEC
S-1/A · Registration statement, amendedAug 14, 2026Offer documentSEC
10-K · Annual reportAug 12, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
FWP · Free writing prospectusAug 7, 2026Offer documentSEC
FWP · Free writing prospectusAug 6, 2026Offer documentSEC
FWP · Free writing prospectusAug 6, 2026Offer documentSEC
S-1/A · Registration statement, amendedAug 6, 2026Offer documentSEC
8-K · Current reportAug 6, 2026Current reportSEC
S-1/A · Registration statement, amendedJul 31, 2026Offer documentSEC
S-1 · Registration statementJul 17, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 30, 2026Other filingsSEC
S-3 · Registration statementJun 18, 2026Offer documentSEC
DRS · Draft registration statementJun 11, 2026Offer documentSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
SCHEDULE 13D · Big-stake noticeMar 25, 2026Big-stake noticeSEC
10-Q · Quarterly reportFeb 6, 2026Quarterly reportSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
S-8 · Registration statement for employee plansNov 25, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 19, 2025Other filingsSEC
8-K · Current reportNov 13, 2025Management or board changeSEC
8-K · Current reportNov 12, 2025Meeting outcomeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
3 · Initial statement of ownershipOct 28, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
POS AM · Amendment to an effective registrationOct 3, 2025Offer documentSEC
POS EXOct 3, 2025Other filingsSEC
424B3 · ProspectusOct 3, 2025Offer documentSEC
DEF 14A · Proxy statementSep 25, 2025Meeting noticeSEC
10-K · Annual reportAug 15, 2025Annual reportSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
8-K · Current reportAug 11, 2025Material contractSEC
424B5 · ProspectusAug 8, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 8, 2025Other filingsSEC
CERT · Exchange's certificate of listingAug 7, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeAug 6, 2025Other filingsSEC
CORRESP · Letter to the SECAug 4, 2025Other filingsSEC
CORRESP · Letter to the SECAug 4, 2025Other filingsSEC
S-1/A · Registration statement, amendedAug 4, 2025Offer documentSEC
CORRESP · Letter to the SECJul 24, 2025Other filingsSEC
CORRESP · Letter to the SECJul 24, 2025Other filingsSEC
8-K · Current reportJul 23, 2025Management or board changeSEC
CORRESP · Letter to the SECJul 22, 2025Other filingsSEC
CORRESP · Letter to the SECJul 22, 2025Other filingsSEC
S-1/A · Registration statement, amendedJul 22, 2025Offer documentSEC
S-1/A · Registration statement, amendedJul 11, 2025Offer documentSEC
S-1 · Registration statementJul 3, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 30, 2025Big-stake noticeSEC
8-K · Current reportJun 27, 2025Current reportSEC
8-K · Current reportJun 24, 2025Meeting outcomeSEC
DEF 14A · Proxy statementJun 2, 2025Meeting noticeSEC
UPLOAD · Letter from the SECMay 20, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftMay 14, 2025Other filingsSEC
DRS · Draft registration statementMay 14, 2025Offer documentSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
PRE 14A · Preliminary proxy statementMay 8, 2025Meeting noticeSEC
PRE 14CMay 7, 2025Meeting noticeSEC
8-K · Current reportMar 28, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
10-Q · Quarterly reportFeb 11, 2025Quarterly reportSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
1-ADec 31, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveDec 3, 2024Other filingsSEC
424B3 · ProspectusDec 2, 2024Offer documentSEC
CORRESP · Letter to the SECNov 29, 2024Other filingsSEC
S-1/A · Registration statement, amendedNov 27, 2024Offer documentSEC
UPLOAD · Letter from the SECNov 26, 2024Other filingsSEC
S-8 · Registration statement for employee plansNov 22, 2024Offer documentSEC
S-1 · Registration statementNov 21, 2024Offer documentSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 8, 2024Meeting outcomeSEC
8-K · Current reportOct 29, 2024Current reportSEC
424B5 · ProspectusOct 29, 2024Offer documentSEC
8-K · Current reportOct 29, 2024Material contractSEC
SC 13G · Big-stake noticeOct 25, 2024Big-stake noticeSEC
8-K · Current reportOct 24, 2024Current reportSEC
424B5 · ProspectusOct 24, 2024Offer documentSEC
8-K · Current reportOct 24, 2024Material contractSEC
8-K · Current reportOct 22, 2024Current reportSEC
424B5 · ProspectusOct 22, 2024Offer documentSEC
8-K · Current reportOct 22, 2024Material contractSEC
DEFA14A · Additional proxy materialOct 21, 2024Meeting noticeSEC
10-K · Annual reportSep 30, 2024Annual reportSEC
DEF 14A · Proxy statementSep 27, 2024Meeting noticeSEC
424B5 · ProspectusSep 25, 2024Offer documentSEC
8-K · Current reportSep 25, 2024Current reportSEC
424B5 · ProspectusSep 24, 2024Offer documentSEC
8-K/A · Current report, amendedSep 24, 2024Current reportSEC
8-K · Current reportSep 24, 2024Material contractSEC
424B5 · ProspectusSep 23, 2024Offer documentSEC
PRE 14A · Preliminary proxy statementSep 17, 2024Meeting noticeSEC
8-K · Current reportAug 20, 2024Current reportSEC
8-K/A · Current report, amendedAug 6, 2024Current reportSEC
8-K · Current reportAug 1, 2024Meeting outcomeSEC
8-K · Current reportJul 30, 2024Management or board changeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 25, 2024Big-stake noticeSEC
DEF 14A · Proxy statementJun 17, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementJun 7, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportApr 19, 2024Current reportSEC
UPLOAD · Letter from the SECApr 5, 2024Other filingsSEC
CORRESP · Letter to the SECMar 15, 2024Other filingsSEC
UPLOAD · Letter from the SECMar 13, 2024Other filingsSEC
8-K · Current reportMar 11, 2024Current reportSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
8-K · Current reportMar 6, 2024Current reportSEC
8-K/A · Current report, amendedMar 4, 2024Current reportSEC
424B5 · ProspectusMar 4, 2024Offer documentSEC
8-K · Current reportMar 4, 2024Material contractSEC
424B5 · ProspectusMar 1, 2024Offer documentSEC
8-K · Current reportMar 1, 2024Current reportSEC
10-Q · Quarterly reportFeb 12, 2024Quarterly reportSEC
8-K · Current reportJan 25, 2024Current reportSEC
8-K · Current reportJan 19, 2024Current reportSEC
424B3 · ProspectusJan 19, 2024Offer documentSEC
4 · Change in ownershipDec 13, 2023Insider tradeSEC
4 · Change in ownershipDec 6, 2023Insider tradeSEC
4 · Change in ownershipDec 6, 2023Insider tradeSEC
4 · Change in ownershipDec 6, 2023Insider tradeSEC
4 · Change in ownershipDec 6, 2023Insider tradeSEC
4 · Change in ownershipDec 6, 2023Insider tradeSEC
4 · Change in ownershipDec 6, 2023Insider tradeSEC
4 · Change in ownershipDec 1, 2023Insider tradeSEC
144 · Notice of proposed saleDec 1, 2023Other filingsSEC
144 · Notice of proposed saleDec 1, 2023Other filingsSEC
8-K · Current reportNov 29, 2023Current reportSEC
8-K · Current reportNov 13, 2023Meeting outcomeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportOct 25, 2023Current reportSEC
DEF 14A · Proxy statementSep 29, 2023Meeting noticeSEC
8-K · Current reportSep 8, 2023Current reportSEC
4 · Change in ownershipSep 7, 2023Insider tradeSEC
144 · Notice of proposed saleSep 5, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 29, 2023Other filingsSEC
424B3 · ProspectusAug 28, 2023Offer documentSEC
UPLOAD · Letter from the SECAug 25, 2023Other filingsSEC
4 · Change in ownershipAug 24, 2023Insider tradeSEC
CORRESP · Letter to the SECAug 24, 2023Other filingsSEC
S-3 · Registration statementAug 18, 2023Offer documentSEC
10-K · Annual reportAug 16, 2023Annual reportSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
424B3 · ProspectusApr 14, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 11, 2023Other filingsSEC
CORRESP · Letter to the SECApr 7, 2023Other filingsSEC
4 · Change in ownershipApr 6, 2023Insider tradeSEC
424B5 · ProspectusApr 6, 2023Offer documentSEC
8-K · Current reportApr 6, 2023Current reportSEC
UPLOAD · Letter from the SECApr 6, 2023Other filingsSEC
CORRESP · Letter to the SECApr 6, 2023Other filingsSEC
S-3 · Registration statementMar 31, 2023Offer documentSEC
8-K · Current reportMar 23, 2023Current reportSEC
8-K · Current reportMar 13, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedMar 10, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMar 7, 2023Big-stake noticeSEC
8-K · Current reportMar 6, 2023Management or board changeSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC
4 · Change in ownershipFeb 22, 2023Insider tradeSEC

This page holds 200 of 515 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BioVie Inc.’s releases · as of Nov 5, 2026

Common shares
10,724,724
Fully diluted
16,724,724

Fully diluted

LineSharesAs of
Common shares10,724,724Nov 5, 2026
Warrants6,000,000Aug 11, 2025

Warrants and options

Lot
Warrants · US$2.50 · expire about Aug 2030

Share count over time

CountShares
Nov 5, 202610,724,724

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Morgan Stanley1.05M9.8%US$1.59MSep 30, 2026
Jane Street231K2.2%US$351KSep 30, 2026
Vanguard108K1.0%US$165KSep 30, 2026
Acadian Asset Management LLC80,8260.75%US$122KSep 30, 2026
Geode Capital75,7740.71%US$115KSep 30, 2026
State Street73,1030.68%US$111KSep 30, 2026
Philadelphia Trust Co50,0100.47%US$76,000Sep 30, 2026
Northern Trust21,8200.20%US$33,166Sep 30, 2026
Gsa Capital Partners LLP21,1340.20%US$32,000Sep 30, 2026
StoneX Group Inc.15,9830.15%US$26,434Sep 30, 2026
All 32 holders
HolderSharesOf the companyValueAs of
Caprock Group, LLC13,0000.12%US$19,760Sep 30, 2026
UBS8,0910.08%US$12,298Sep 30, 2026
Allworth Financial LP5,6500.05%US$8,588Sep 30, 2026
Rockefeller Capital Management L.P.5,0000.05%US$7,600Sep 30, 2026
Tower Research Capital LLC (TRC)4,4270.04%US$6,729Sep 30, 2026
SBI Securities Co., Ltd.1,6670.02%US$2,534Sep 30, 2026
PNC Financial Services Group, Inc.1,000<0.01%US$1,520Sep 30, 2026
Pinnacle Financial Group, Inc.500<0.01%US$760Sep 30, 2026
BFC Planning, Inc.430<0.01%US$654Sep 30, 2026
Tradewinds Capital Management, LLC10<0.01%US$16Sep 30, 2026
NewEdge Advisors, LLC10<0.01%US$15Sep 30, 2026
Osaic Holdings, Inc.8<0.01%US$12Sep 30, 2026
Financial Perspectives, Inc6<0.01%US$9Sep 30, 2026
JPMorgan5<0.01%US$8Sep 30, 2026
Harbour Investments, Inc.3<0.01%US$5Sep 30, 2026
Caitong International Asset Management Co., Ltd2<0.01%US$3Sep 30, 2026
Barclays1<0.01%US$2Sep 30, 2026
BNP Paribas1<0.01%US$2Sep 30, 2026
Albion Financial Group1<0.01%US$2Sep 30, 2026
Jones Financial Companies Lllp1<0.01%US$2Sep 30, 2026
Danske Bank A/S1<0.01%US$2Sep 30, 2026
Fidelity00.00%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund70,9060.66%US$138KJun 30, 2026
Fidelity Extended Market Index Fund55,4530.52%US$78,743May 31, 2026
Fidelity Series Total Market Index Fund10,8980.10%US$15,475May 31, 2026
Fidelity Total Market Index Fund2,4010.02%US$3,409May 31, 2026
Fidelity Nasdaq Composite Index Fund230<0.01%US$327May 31, 2026
Blackstone Alternative Multi-Strategy Fund10<0.01%US$19Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Do Cuong V
Director, Officer: President & CEO
Buy2,500USD 1.00US$2,493Nov 18, 2026
Do Cuong V
Director, Officer: President & CEO
Buy2,500USD 1.16US$2,906Nov 13, 2026
Kim Joanne Wendy
Officer: Chief Financial Officer
Buy2,500USD 2.18US$5,450Aug 28, 2026
Chappell Amy Suzon
Director
Buy727USD 2.16US$1,570Aug 28, 2026
Palumbo Joseph M
Officer: Chief Medical Officer
Buy4,843USD 2.16US$10,461Aug 28, 2026
Do Cuong V
Director, Officer: President & CEO
Buy15,210USD 2.08US$31,637Aug 27, 2026

Big stakes

StakeStakeSharesDateFiling
Alta Partners LLC8.40%687KAug 12, 2026Schedule 13G
Morgan Stanley8.00%605KJun 30, 2026Schedule 13G
DO CUONG V5.03%399KJan 5, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Steve Gorlin
Other companies: PolarityTE Inc. (Director · Feb 8, 2017 – Aug 6, 2019 · Past); ImmunityBio, Inc. (Director · Jul 27, 2015 – Jun 10, 2020 · Past); Catasys Inc (Director · Nov 6, 2014 – Jun 15, 2018 · Past); DARA Biosciences Inc (Director · Feb 12, 2008 – May 15, 2012 · Past); MiMedx Group, Inc (Director · Feb 8, 2008 – May 16, 2013 · Past); Medivation Inc (Director · Dec 31, 2005 – Dec 31, 2005 · Past)
Director · Jun 30, 2020 – Nov 9, 2023 · Past
Cuong Do
Other companies: Adagene, Inc. (Independent Director · Since at least Mar 18, 2026); Spark I Acquisition Corp. (Director · Oct 5, 2023 – Oct 5, 2023 · Past); Merck & Company, Inc. (EVP & Chief Strategy Officer · Oct 3, 2011 – May 6, 2013 · Past); TE Connectivity plc (SVP, Corp. Strategy & Bus. Dev · Jun 16, 2010 – Sep 15, 2011 · Past)
President & Chief Executive Officer · Since at least Jul 1, 2018
James Paul Lang
Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Dec 4, 2025); OptimizeRx Corporation (Director · Since at least Sep 30, 2019)
Director · Since at least Jun 30, 2020
Emily Daniele
Other companies: Halozyme Therapeutics, Inc. (Chief Operating Officer · Dec 17, 2025 – Nov 5, 2026 · Past)
Chief Operating Officer · Dec 17, 2025 – Nov 5, 2026 · Past
Jim Lang
Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Dec 8, 2025)
Independent Director · Since at least Dec 17, 2025
Michael Sherman
Other companies: Catasys Inc (Director · Jul 14, 2017 – Feb 12, 2020 · Past)
Independent Director · Since at least Oct 25, 2017
Amy ChappellIndependent Director · Since at least Jul 22, 2025
Chris ReadingSenior Vice President Alzheimer's Disease Program · Since at least Nov 4, 2026
Christopher ReadingEVP Neuroscience R&D · Jul 1, 2021 – Feb 16, 2023 · Past
Clarence AhlemSenior Vice President Operations · Since at least Jul 1, 2021
All 20 people
PersonSeat
David MorseChief Regulatory Officer and Senior Vice President · Since at least Nov 5, 2026
Hari KumarDirector · Jan 2, 2019 – Jun 30, 2020 · Past
Joanne Wendy KimChief Financial Officer · Since at least Oct 1, 2018
Jonathan M AdamsEVP Liver Cirrhosis Programs · Jun 30, 2020 – Feb 2, 2022 · Past
Joseph M. PalumboExecutive Vice President, Research & Development and Chief Medical Officer · Since at least Aug 28, 2026
Kameel FaragIndependent Director · Since at least Jul 22, 2025
Penelope MarkhamSenior Vice President Liver Disease and Long COVID Programs · Since at least Nov 1, 2018
Sigmund RogichDirector · Since at least Jun 30, 2020
Sig RogichIndependent Director · Since at least Nov 5, 2026
Wendy KimChief Financial Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about BioVie Inc.